Search results
Results from the WOW.Com Content Network
Genetic variations in BCL3 gene have been associated with late-onset Alzheimer's disease (LOAD) and chronic lymphocytic leukemia. β-amyloid accumulation in neurons of Alzheimer's patients results in activation of NF-κB, which induces BCL3 expression. [16] Increased expression of BCL3 has been observed in the brains of patients with LOAD. [17]
B-cell CLL/lymphoma refers to a family of genes associated with certain types of lymphoma and leukemia. Although named for B-cell chronic lymphocytic leukemia, they can be associated with other malignancies. Members include: CCND1 (also known as "BCL1") BCL2; BCL3; BCL5; BCL6, BCL6B; BCL7A, BCL7B, BCL7C; BCL8; BCL9; BCL10; BCL11A, BCL11B
A study in Japan found that approximately 26% of relapsed B-cell lymphoma patients lost CD20 expression during treatment with rituximab. Lab tests involving 5-Aza showed that CD20 expression and rituximab sensitivity could be restored in some cases using epigenetic drug treatment. [10] Rituximab (Rituxan. The mechanism of action of Rituximab ...
In November 2018, in the United States, venetoclax was approved in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. [18]
In July 2014, the FDA granted breakthrough therapy status to blinatumomab for the treatment of acute lymphoblastic leukemia (ALL). [12] In October 2014, Amgen's Biologics License Application for blinatumomab was granted priority review designation by the FDA, thus establishing a deadline of 19 May 2015, for completion of the FDA review process ...
Boron reacts with halogens to give the corresponding trihalides. Boron trichloride is, however, produced industrially by chlorination of boron oxide and carbon at 501 °C.. B 2 O 3 + 3 C + 3 Cl 2 → 2 BCl 3 + 3 CO
A woman who underwent a trial immunotherapy as a child for neuroblastoma — an aggressive nerve tissue tumor that occurs often in children under 5 — has since been in remission for 18 years ...
Tisagenlecleucel is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; or adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma ...